Saluda Medical Statistics
Total Valuation
Saluda Medical has a market cap or net worth of AUD 148.69 million. The enterprise value is 34.24 million.
| Market Cap | 148.69M |
| Enterprise Value | 34.24M |
Important Dates
The next estimated earnings date is Wednesday, May 27, 2026.
| Earnings Date | May 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Saluda Medical has 252.02 million shares outstanding. The number of shares has increased by 1,086.55% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 252.02M |
| Shares Change (YoY) | +1,086.55% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.30% |
| Owned by Institutions (%) | 29.02% |
| Float | 5.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.30 |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.09 |
| EV / Sales | 0.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.19 |
Financial Position
The company has a current ratio of 6.41, with a Debt / Equity ratio of 0.65.
| Current Ratio | 6.41 |
| Quick Ratio | 4.93 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.62 |
| Interest Coverage | -4.01 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -67.38% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 857,430 |
| Profits Per Employee | -2.85M |
| Employee Count | 133 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Saluda Medical has paid 1.13 million in taxes.
| Income Tax | 1.13M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.85 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 25.03 |
| Average Volume (20 Days) | 218,430 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Saluda Medical had revenue of AUD 114.04 million and -378.77 million in losses. Loss per share was -9.84.
| Revenue | 114.04M |
| Gross Profit | 54.43M |
| Operating Income | -194.09M |
| Pretax Income | -242.65M |
| Net Income | -378.77M |
| EBITDA | -191.58M |
| EBIT | -194.09M |
| Loss Per Share | -9.84 |
Balance Sheet
The company has 227.02 million in cash and 112.57 million in debt, giving a net cash position of 114.45 million or 0.45 per share.
| Cash & Cash Equivalents | 227.02M |
| Total Debt | 112.57M |
| Net Cash | 114.45M |
| Net Cash Per Share | 0.45 |
| Equity (Book Value) | 174.00M |
| Book Value Per Share | 0.69 |
| Working Capital | 273.74M |
Cash Flow
In the last 12 months, operating cash flow was -181.16 million and capital expenditures -1.87 million, giving a free cash flow of -183.02 million.
| Operating Cash Flow | -181.16M |
| Capital Expenditures | -1.87M |
| Depreciation & Amortization | 2.33M |
| Net Borrowing | 141.61M |
| Free Cash Flow | -183.02M |
| FCF Per Share | -0.73 |
Margins
Gross margin is 47.73%, with operating and profit margins of -170.20% and -213.77%.
| Gross Margin | 47.73% |
| Operating Margin | -170.20% |
| Pretax Margin | -212.78% |
| Profit Margin | -213.77% |
| EBITDA Margin | -168.00% |
| EBIT Margin | -170.20% |
| FCF Margin | n/a |
Dividends & Yields
Saluda Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,086.55% |
| Shareholder Yield | -1,086.55% |
| Earnings Yield | -254.73% |
| FCF Yield | -123.09% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Saluda Medical has an Altman Z-Score of -3.24 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.24 |
| Piotroski F-Score | 2 |